Patents by Inventor C. Andrew Stewart

C. Andrew Stewart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED CELLS SECRETING THERAPEUTIC ENZYMES
    Publication number: 20230174944
    Abstract: Provided herein are mammalian cells comprising a first exogenous nucleic acid encoding a DNAse protein and a second exogenous nucleic acid encoding another DNAse protein, such as DNASE1 protein and DNASE1L3 protein, that have improved properties, including the ability to degrades extracellular chromatin and remove Neutrophil Extracellular Traps (NETs). Use of these cells, including the use in the treatment of a subject in need thereof, is also contemplated.
    Type: Application
    Filed: April 15, 2021
    Publication date: June 8, 2023
    Applicant: Cartesian Therapeutics, Inc.
    Inventors: Yi Zhang, C. Andrew Stewart, Shaji Daniel, Metin Kurtoglu, Murat V. Kalayoglu
  • ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20220089678
    Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 24, 2022
    Applicant: Cartesian Therapeutics, Inc.
    Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
  • Anti-BCMA chimeric antigen receptors
    Patent number: 11220535
    Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: January 11, 2022
    Assignee: Cartesian Therapeutics, Inc.
    Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
  • ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20210221868
    Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.
    Type: Application
    Filed: January 22, 2021
    Publication date: July 22, 2021
    Applicant: Cartesian Therapeutics, Inc.
    Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat Kalayoglu, Michael S. Singer
  • Anti-BCMA chimeric antigen receptors
    Patent number: 10934337
    Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 2, 2021
    Assignee: Cartesian Therapeutics, Inc.
    Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
  • ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20200291087
    Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.
    Type: Application
    Filed: March 20, 2020
    Publication date: September 17, 2020
    Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
  • Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
    Patent number: 9475839
    Abstract: A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: October 25, 2016
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Nadya I. Tarasova, Giorgio Trinchieri, Howard A. Young, C. Andrew Stewart, Marco A. Cardone, Alan O. Perantoni
  • PEPTIDE-BASED INHIBITOR OF INTERLEUKIN-10 OR INTERFERON-GAMMA SIGNALING
    Publication number: 20130109619
    Abstract: A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.
    Type: Application
    Filed: May 11, 2011
    Publication date: May 2, 2013
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Nadya I. Tarasova, Giorgio Trinchieri, Howard A. Young, C. Andrew Stewart, Marco A. Cardone, Alan O. Perantoni